Skip to main content
Press Releases

Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board

By May 12, 2021No Comments
Cedars-Sinai Veteran Physician Joins Four Additional Clinical, Oncology and Cannabinoid Experts to Guide the Company’s Research and Scientific Programs

NAPLES, Fla.May 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Arash Asher, M.D., Director of Cancer Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center, to the Company’s Scientific Advisory Board.


“We believe that Dr. Asher’s decision to join Enveric’s Scientific Advisory Board gives the Company a significant advantage given his extensive time and expertise at Cedars-Sinai,” said David Johnson, Chairman and CEO, Enveric Biosciences. “Our mission at Enveric is focused on improving cancer patients’ quality of life through leveraging the power of cannabinoid medicines. Dr. Asher’s deep knowledge of chemotherapy-induced peripheral neuropathy and more should help us achieve this goal of bringing safe, effective care to cancer patients who continue to suffer from their treatment side effects.”


Dr. Asher’s affiliations with Cedars-Sinai also include serving as Associate Professor in the Departments of Medicine and Physical Medicine and Rehabilitation. His clinical and research interests focus on rehabilitating cancer patients to help restore their maximal functional capacity and quality of life. Additionally, Dr. Asher’s expertise is in the non-pharmacologic management of pain, cancer-related fatigue, cognitive dysfunction, neuropathy, exercise prescription for cancer patients and other musculoskeletal problems.


Dr. Asher completed a physical medicine and rehabilitation residency at the UCLA / West Los Angeles Veterans Affairs program, as well as a cancer rehabilitation fellowship at the MD Anderson Cancer Center. He is board-certified by the American Board of Physical Medicine and Rehabilitation and Hospice and Palliative Medicine.


Additional members of Enveric’s Scientific Advisory Board include:


  • Michael J. Zelefsky, M.D. – Professor of Radiation Oncology in the Department of Radiation Oncology, and Chief, Brachytherapy Service, at Memorial Sloan Kettering Cancer Center, with a specialization in clinical research
  • Angus Dalgleish, M.D. FMedSci – Foundation Professor of Oncology at St Georges’, University of London. Principal of the Institute of Cancer Vaccines and Immunotherapy (ICVI)
  • James Perry, M.D. – Neuro-Oncologist, Sunnybrook Research Institute, and Professor, University of Toronto, with a specialization in clinical research
  • Zvi Vogel, Ph.D. – Professor at the Neurobiology Department of the Weizmann Institute, with a specialization in Cannabinoid research, as well as a patent contributor


Enveric Biosciences held its first Scientific Advisory Board meeting on April 25, 2021, during which the Board discussed and reviewed Enveric’s radiodermatitis and glioblastoma clinical development plans in detail. The group supported the Company’s plan and the identification of ways to accelerate its research and development programs focused on cannabinoids as a supportive care therapy.


About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit


Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267 /


Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630 /


Cision View original content:


SOURCE Enveric Biosciences

Leave a Reply